Details of issuance or disposal
Monthly report on the exercise status of Series 18 Stock Acquisition Rights issued through third-party allotment (with Exercise Price Adjustment and Exercise Suspension Clauses)
Number of shares delivered during the month: — shares (new shares: — shares; transferred treasury shares: — shares)
The lower thin line represents the existing number of shares to which these shares will be added.
Exercise ratio during the month: –%. Dilution ratio relative to the number of shares outstanding: Not disclosed
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly report on the exercise status of Series 18 Stock Acquisition Rights issued through third-party allotment (with Exercise Price Adjustment and Exercise Suspension Clauses) |
| Number of shares to be issued or disposed of | Number of shares delivered during the month: — shares (new shares: — shares; transferred treasury shares: — shares) |
| Intended allottee | EVO FUND (issued on 4 December 2025) |
| Dilution Rate | Exercise ratio during the month: –%. Dilution ratio relative to the number of shares outstanding: Not disclosed |
| Total number of issued shares | 3,167,228 shares (as of the end of the month preceding the target month) → Not disclosed |
| Exercise price | The exercise price during the month ranged from ¥474 to ¥597. Details of the adjustment clause and the adjustment floor: Not disclosed |
| Number of Stock Acquisition Rights | Total number issued: 10,000; unexercised rights as of the end of the preceding month: 7,830; unexercised rights as of the end of the month: 7,830; rights exercised during the month: – |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | 4 December 2025: Issuance of Series 18 Stock Acquisition Rights allocated to EVO FUND (total issued: 10,000 rights) |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company only reported the monthly exercise status for March 2026 and did not state why there were no exercises.